{"page":{"totalFilteredElements":14},"studies":[{"active":true,"description":"Niraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)","eudractNumber":"2024-516066-11-00","id":8116,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":"NCT05009082","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-21T09:30:36+02:00","shortTitle":"AGO-Ovar 28","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability,&#160;Pharmacokinetics, and Efficacy of AMG 193 Alone or in&#160;Combination With Other Therapies in Subjects With&#160;Advanced Thoracic Tumors With Homozygous MTAPdeletion<br />(Master Protocol)","eudractNumber":"2024-511253-21","id":9279,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"MTAP (methylthioadenosine phosphorylase)","id":"mt_260"}],"nctNumber":"NCT06333951","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2025-03-20T09:14:14+01:00","shortTitle":"AMG 193 20230167","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"<p style=\"margin:0in;\">A Phase 1b Study\nEvaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193\nin Combination With other Therapies in Subjects With Advanced Gastrointestinal,\nBiliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion</p><p style=\"margin:0in;\"><br /></p>\n\n<p style=\"margin:0in;\">Subprotocol A: AMG 193 in Combination with\nGemcitabine, Cisplatin, and Pembrolizumab in Subjects with Advanced BTC With\nHomozygous MTAP-deletion</p><p style=\"margin:0in;\"><br /></p>\n\n<p style=\"margin:0in;\">Subprotocol B: AMG 193 in Combination with\nmFOLFIRINOX or with Gemcitabine and Nab-paclitaxel in Subjects with Advanced\nPDAC with Homozygous MTAP-deletion</p>","eudractNumber":"2024-511195-33","id":9821,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[{"name":"MTAP (methylthioadenosine phosphorylase)","id":"mt_260"}],"nctNumber":"NCT06360354","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2024-10-30T09:26:10+01:00","shortTitle":"AMG 193 20230223","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<p class=\"MsoNormal\">A First &#8211; in Human\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\n764532 administered by repeated intravenous infusions in patients with Small\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3</p>","eudractNumber":"2019-000729-31","id":6385,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[{"name":"DLL3 (Delta-like 3)","id":"mt_29"}],"nctNumber":"NCT04429087","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2021-10-14T12:29:06+02:00","shortTitle":"BI 1438-0001","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 1/2 Study of BMS-986340 as Monotherapy and in\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors&#160;<br /></p><p class=\"MsoNormal\">EUDRA-CT Nummer ge&#228;ndert 18.12.2023<br /></p><p class=\"MsoNormal\">von 2021-001188-26 auf&#160; 2023-503651-10-00<br /></p>","eudractNumber":"2023-503651-10","id":7045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[],"nctNumber":"NCT04895709 ","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-07-14T09:20:02+02:00","shortTitle":"BMS CA052-002","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma&#160;(QUINTESSENTIAL-2)","eudractNumber":"2022-501346-30-00","id":9854,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06615479","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-01T09:47:06+02:00","shortTitle":"BMS CA088-1007","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 2 Study to Evaluate the Efficacy and Safety of\nBelzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced\nPheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)</p>","eudractNumber":"2020-005028-13","id":7072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":"NCT04924075","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-03-01T11:25:39+01:00","shortTitle":"Belzutifan/MK-6482 for the treatment of PPGL or pNET","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients","eudractNumber":"2022-000637-16","id":8358,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR-","id":"mt_50"},{"name":"PgR+","id":"mt_49"}],"nctNumber":"NCT05452213","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-11-23T13:59:57+01:00","shortTitle":"CAPTOR-BC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"FUTURE platform trial<div>A phase II platform trial of futibatinib in combinaton with (chemo)immunotherapy in colorectal cancer and other solid tumor entities</div>","eudractNumber":"2024-517573-24-00","id":11575,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-12-09T12:34:40+01:00","shortTitle":"FUTURE-001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III \"PREVENT\" Trial of the AIO /CAOGI /ACO<div><br /></div>","eudractNumber":"2017-003832-35","id":6238,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"}],"mutations":[],"nctNumber":"NCT04447352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-12-16T14:24:11+01:00","shortTitle":"HIPEC/FLOT9 (PREVENT)","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]}]}